Kornimate/medical-research-clean huggingface dataset:
the efficacy of serum pepsinogen for prediction of metachronous gastric neoplasm

Conditions: Gastric Cancer

Summary: after endoscopic resection of early gastric cancer (egc), there remained concerned about the development of the metachronous gastric neoplasm (mgn). the aim of this study was to evaluate the role of h. pylori eradication for reducing mgn after esd and the efficacy of serum pepsinogen (pg) for predicting development of mgn after endoscopic submucosal dissection (esd) for egc and to evaluate other risk factors for the incidence of mgn. the investigators enrolled the participants who were tested serum pg i and ii at the time of esd for egc, from january 2007 to may 2013 in single tertiary center, retrospectively. the baseline characteristics of the participants, h. pylori status, and serum pepsinogen were analyzed for the development of the mgn.


Eligibility criteria:
inclusion criteria: * the patients who tested serum pg concentration test and h. pylori status at the time of esd and revealed pathologically complete en bloc resection after esd for egc. exclusion criteria: * previous history of er; proven pathologically incomplete resection or lympho-vascular invasion on the resected esd specimen; additional treatment after esd; and follow-up loss less than 2 years.

Keywords: early gastric cancer endoscopic submucosal dissection serum pepsinogen helicobacter pylori
effects of acupuncture at st36 and pc6 on blood pressure and endothelial dysfunction in hypertensive patients

Conditions: Hypertension

Summary: this is randomised, controlled study about effects of acupuncture on blood pressure and endothelial dysfunction in stage i hypertension patient without medication. subject will receive 8 weeks of either acupuncture or sham acupuncture, measuring fmd and blood test before and after treatment.


Eligibility criteria:
inclusion criteria: * patients age 18-70 diagnosed stage i hypertension ( jnc-7) without taking hypertensive medication exclusion criteria: * secondary hypertension * dm * history of cardiovascular disease * taking hypertensive medication * taking hyperlipidemic medication * smoking * pregnancy or feeding woman * cannot follow indication or there is no agreement of patient and conservator * investigator decide inappropriate to trial

Keywords: efficacy acupuncture hypertension
pharmacodynamics of tafluprost 0.0015% eye drops: a comparison between the preserved and unpreserved formulation

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: the objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure \[iop\]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma or ocular hypertension. the primary aim of this study is to show that iop reduction between the two formulations is equivalent at the end of the 4 week treatment period.


Eligibility criteria:
inclusion criteria: * age 18 years or more * a diagnosis of open angle glaucoma or ocular hypertension * prior use of prostaglandin(s) * intra ocular pressure of 22-34 mmhg in at least one eye exclusion criteria: * females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception * previous participation in any clinical trial in which tafluprost was an investigational drug or use of contact lenses at screening or during the study * presence of any abnormality or significant illness that could be expected to interfere with the study

Keywords: ocular hypertension
comparative analgesic effect after total knee arthroplasty between intraosseous and peri-articular injection

Conditions: Pain Postoperative; Total Knee Anthroplasty; Functional Outcomes

Summary: the goal of this rct is to compare analgesic effect after total knee arthroplasty between intraosseous multimodal analgesic agent injection versus periarticular injection. the main question\[s\] it aims to answer are: does intraosseous multimodal analgesic cocktail injection have more post-operative analgesic effect than peri-articular injection in patients who have done tka (p)? participants will randomized to intraosseous injection group or peri-articular injection group and will record the 100-mm vas pain scores for 2 weeks after tka. researchers will compare to peri-articular injection group to see pain and functional outcomes after tka.

intra-operatively, you will be randomly assigned to receive intraosseous multimodal analgesic agent injection or peri-articular multimodal analgesic agent injection along with other standard medications. in the intraosseous injection group: participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + morphine 5mg + ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation. in the peri-articualr injection group: participants received combinations of the same drug and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. and the last 25 ml of multimodal analgesic drugs were injected into quadriceps.

Eligibility criteria:
inclusion criteria: * 50 - 80 yrs of age asa classification: 1-3 unilateral tka exclusion criteria: * secondary oa knee previous knee surgery can't undertaken spinal block and adductor canal block renal insuf. (crcl \ 35 kg/m2 allergy to study drugs history of coronary disease hb \< 10 (g/dl) can't understand 100mm-vas assessment refuse to recruit in the study, or refuse follow up using opioid in 5 days before surgery unstable vital sign history current vte using anti-platelet or anti-coagulation medicine severe deformity

Keywords: peri-articular injection intraosseous injection multimodal analgesia cocktail tka pain postoperative functional outcomes
prehospital deaths from spontaneous subarachnoid haemorrhages

Conditions: Subarachnoid Hemorrhage

Summary: in this study we aim to determine the incidence of fatal spontaneous subarachnoid haemorrhage outside hospital. also, we aim to investigate these patient´s pattern of contact to the health care system immediately before their death and to describe the circumstances under which they died.

sudden death due to spontaneous subarachnoid hemorrhage (ssah) has been known for decades. an older metaanalysis found a combined overall risk of sudden death from ssah of 12.4% (the individual studies reported incidences of 3-21%). in a recent study 98 out of 445 patients with ssah died in the prehospital phase. in addition to the high proportion of ssah-patients that die, they are also much younger than those who die from intracerebral hemorrhage; the median age of ssah-patients that die suddenly is 54 years versus 71 years among patients with intracerebral hemorrhage. predictors for sudden death have been found to include living alone, smoking and high systolic blood pressure, as well as hemorrhage in the posterior circulation. while some patients may die at onset of the hemorrhage, others may have experienced symptoms longer. the clinical presentation of ssah varies and some studies report as little as 40% of patients to have presented with classic textbook symptoms. half are initially in an intact neurological state. these patients may have been in contact with the health care system but not admitted. in recent years the copenhagen emergency medical coordinations center has implemented an electronic decision support tool. if this has reduced the proportion of patients with ssah that die outside hospital is unknown. primary aim: the primary aim of this study is to determine the incidence of fatal spontaneous subarachnoid hemorrhage in the capital region of denmark, before being admitted to hospital. secondary analyses: * proportion of deceased patients that have been in contact with a general practitioner, on-call general practitioner, the copenhagen emergency medical services or admitted to hospital within 72 hours of their death. * proportion of deceased patients with a history of significant illness immediately before their dead, but without contacting the health care system. * for patients in contact with the copenhagen emergency medical services, their primary complaint and the initiated response. * descriptive characteristics of deceased with respect to age, gender, body mass index and comorbidities. * time trends in the incidence of prehospital death from ssah over the years 2008-2017.

Eligibility criteria:
inclusion criteria: * must be registered at the department of forensic medicine with spontaneous subarachnoid hemorrhage as the cause of death, deceased between 2008 and 2017, and found in the capital region of denmark. exclusion criteria: -

Keywords: subarachnoid hemorrhage emergency medical coordination center emergency medical service
additional gluteal control training for low back pain with functional leg length inequality

Conditions: Low Back Pain, Recurrent

Summary: low back pain (lbp) is a prevalent musculoskeletal disorder. a variety of exercise interventions which were designed as randomized control trails (rcts) have been studied and shown effectiveness in improving pain and disability. these exercises typically focus on the abdominal and back musculature strength. however, many lbp patients did not show any improvement in their symptom after they carry out those exercise programs.

low back pain (lbp) is a prevalent musculoskeletal disorder. a variety of exercise interventions which were designed as randomized control trails (rcts) have been studied and shown effectiveness in improving pain and disability. these exercises typically focus on the abdominal and back musculature strength. however, many lbp patients did not show any improvement in their symptom after they carry out those exercise programs. some authors consider that this type of low back pain may be caused by leg length inequality (lli) in these patients, which resulted from poor gluteal neuromuscular control or muscles' imbalance. in consideration of few studies have been done for investigating the effects of gluteal muscles control training in lbp. thus, the purpose of this study is to investigate the effect of additional gluteal muscles control training on improving functional lli in patients with lbp. we hypothesized that gluteal muscle control training would be more effective in self-reported pain, and their functional disability would be improve after 6-week training program than control training group.

Eligibility criteria:
inclusion criteria: * non-specific lbp (from inferior rib margin to the gluteal fold) * more than 3 months * visual analog scale ≧5 (in past one month) * pelvic innominate rotation (anterior rotation in dominant side) exclusion criteria: * history of fracture or surgery * congenital anomalies in the spine, pelvis, or lower limbs * recent trauma, tumor, pregnancy or scoliosis * lower extremity paresthesia, unknown weakness * bowel and bladder dysfunction * predominant lower extremity pain with standing * presence of system illness, no reasoning weight loss, predominant night pain * specific sacroiliac joint dysfunction
anti-ceacam5 adc m9140 in chinese participants with solid tumors (proceade-crc-02)

Conditions: Solid Tumors; Colorectal Cancer

Summary: the purpose of this study is to evaluate the safety and early clinical activity of m9140 in chinese participants with locally advanced or metastatic colorectal cancer (crc).


Eligibility criteria:
inclusion criteria: * participants with documented histopathological diagnosis of locally advanced or metastatic crc, who were intolerant/refractory to or progressed after standard systemic therapies for the advanced/metastatic stage that included and are restricted to a fluoropyrimidine, irinotecan, a platinum agent (e.g. oxaliplatin), an anti-egfr agent (if clinically indicated, i.e. ras/braf wt), and an anti-vegf agent. participants may have received previous treatment with trifluridine/tipiracil and/or regorafenib or fruquintinib, if locally indicated and available. participants with a known msi-h status must have received treatment with an immune checkpoint inhibitor (if locally indicated and available) unless contraindicated * eastern cooperative oncology group performance status (ecog ps) below or equal to 1 * participants with adequate hematologic, hepatic and renal function as defined in protocol * other protocol defined inclusion criteria could apply exclusion criteria: * participant has a history of malignancy within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years) * participants with known brain metastases, except those meeting the following criteria: brain metastases that have been treated locally and are clinically stable for at least 4 weeks prior to the start of treatment; no ongoing neurological symptoms that are related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable) * participants with diarrhea (liquid stool) or ileus grade \> 1 * cerebrovascular accident/stroke (\< 6 months prior to enrollment) * other protocol defined exclusion criteria could apply

Keywords: adc anti-ceacam5 colorectal cancer solid tumors
compassionate use of defibrotide for patients with veno-occlusive disease of the liver

Conditions: Hepatic Veno-occlusive Disease

Summary: veno-occlusive disease (vod) of the liver is a significant complication for some patients undergoing hematopoietic stem cell transplantation. this disease is thought to be a toxicity secondary to chemotherapy or radiation-induced damage to the epithelial cells of the blood vessels in the liver. vod is categorized as mild, moderate or severe. historically, there has been no method to treat the disease. recently, however, there have been investigations into the use of a new agent called defibrotide. the primary purpose of this protocol is to provide defibrotide to patients with severe vod. because this drug has not been approved by the fda, use of this medication under the auspices of this ind treatment plan is for compassionate use only.

secondary objectives of this protocol include the following: * to describe the toxicities of defibrotide in patients with vod. * to describe the response rate of vod in patients receiving defibrotide.

Eligibility criteria:
inclusion criteria: patients with clinical or pathologic diagnosis of veno-occlusive disease. the following criteria will be used: 1. hyperbilirubinemia (greater than or equal to 2mg/dl) and two of the following: (hepatomegaly, ascites, or weight gain \[greater than or equal to 5% of baseline\]); or, 2. patient who do not fulfill criteria in #1 but who have pathologic or radiographic evidence of vod.

Keywords: hepatic veno-occlusive disease
difference in gc-induced adrenal insufficiency in ra related to polymorphisms in the glucocorticoid receptor gene

Conditions: Rheumatoid Arthritis

Summary: development of glucocorticoid (gc)-induced adrenal insufficiency is a serious adverse effect of gc treatment. it is today not possible to predict this adverse effect. the project aims at investigating a possible individual aspect, which may render subjects more or less sensitive to glucocorticoids, and thereby influence development of gc induced adrenal insufficiency. the hypothesis is that subjects with one or another of the polymorphisms in the gc receptor gene will either have increased or diminished gc sensitivity. this may be responsible for differences in development of gc induced adrenal insufficiency.

blood is sampled from patients with rheumatoid arthritis (ra), fulfilling the inclusion criteria and patients are genotyped for the snps n363s, bcli, er22/23ek and 9β and grouped according to haplotypes. snps will be determined by polymerase chain reaction (pcr). patients will be included for a synacthen test, to evaluate their adrenal function. information from the results of the study will be able to assist clinicians to identify patients at risk and thus individualize gc therapy in a tailored fashion. results of the study will be important for all patient groups worldwide on gc therapy.

Eligibility criteria:
inclusion criteria: * adult patients \> 18 years) * caucasian classified with rheumatoid arthritis. * 1987 acr-classification criteria. * prednisolone min 5mg/day for at least 6 months. * presence of either bcli (high gc sensitivity) or 9β (low gc sensitivity)polymorphisms, or wildtype for for all 4 snps studied. patients with or without these polymorphisms were invited to a synacthen® test, but patients with a mixed hetero- and homozygote genotype were not exclusion criteria: * other major organ disease * females pregnant * females not willing to pause estrogen-containing medications 6 weeks prior to synacthen® test * unable to give a written informed content

Keywords: glucocorticoid polymorphism glucocorticoid receptor gene rheumatoid arthritis adrenal insufficiency prednisolone treatment
prognostic awareness and patient-physician communication in malignant glioma

Conditions: Malignant Glioma

Summary: the purpose of this study is to learn more about the understanding patients with brain tumors have of their disease and their communication with their physician. ultimately, we hope to use these findings to improve communication between patients and their doctors.


Eligibility criteria:
inclusion criteria: patient inclusion criteria * age greater than or equal to 18 * diagnosis of any who grade iii or iv glioma * admitted to the inpatient neurology service * has had at least one outpatient visit with a neuro-oncologist at mskcc fluent in english caregiver inclusion criteria * age greater than or equal to 18 * identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her physical or emotional assistance. * the patient has himself or herself agreed to participate in this study exclusion criteria: patient exclusion criteria * a patient will be excluded if the glasgow coma scale is less than 15. the patient must be oriented to self, age, place, and year, and month. * aphasia precluding comprehension and verbalization of consent to participate * patients who cannot verbally demonstrate their understanding of the risks, benefits, and alternatives to participating in the study. this evaluation will take place for otherwise eligible and willing participants, and it will be performed by the np or md clinician who is obtaining informed consent and will be documented in the medical record. caregiver exclusion criteria * no eligible caregivers who can complete the brief assessment in person or via telephone will be excluded

Keywords: patient-physician communication brain cancer 13-253
prolactin levels in type 2 diabetic patients with stage iii periodontitis

Conditions: Type 2 Diabetes Mellitus

Summary: evaluate the role of prolactin hormone in the pathogenesis of periodontitis by assessing its local gingival levels and assess clinical parameters in patients who have type two diabetes

periodontal examination at baseline, all participants received a full-mouth clinical examination, and the following periodontal parameters will be recorded: plaque index (pi) (19), gingival index (gi) (20), pocket depth (pd), and clinical attachment loss (cal). initial periodontal examination, full mouth scaling and root planning (srp), clinical measurements before and after treatment, gingival crevicular fluid sampling as well as reinforcement of oral hygiene at baseline and during follow-up evaluations will be performed by the same periodontist (e.a.). reinforcement of oral hygiene will be done every month for 3 months. gingival fluid sampling: gingival crevicular fluid (gcf) collection will be done the second day after clinical examination to prevent the contamination of sample with blood associated with the probing of inflamed sites. samples will be collected from the buccal aspects of two interproximal sites in teeth that had the highest signs of inflammation and attachment loss for periodontitis groups, this will be done before, and 3 months after srp. for the control group, samples will be collected from the upper first molar. the samples will be assayed for prl by using an enzyme linked immunosorbent assay (elisa) kits. patient's examinations: glycosylated hemoglobin (hemoglobin a1c) test and body mass index will be measured to all participants.

Eligibility criteria:
inclusion criteria: * age range from 18 to 60 years * stage iii periodontitis * type 2 diabetes * only patients signing informed written consents exclusion criteria: * pregnancy or lactation * any known systemic disease * any type of previous periodontal treatment (surgical or non-surgical) in the preceding 6 months * smoking (former or current)

Keywords: diabetes mellitus ,type 2 periodontitis gingival crevicular fluid prolactin non- surgical periodontal treatment
patient controlled methylphenidate for cancer related fatigue: a double blind, randomized, placebo controlled trial

Conditions: Fatigue; Cancer

Summary: to determine the effectiveness of patient controlled methylphenidate as compared to placebo for the management of cancer related fatigue as determined by the functional assessment of chronic illness therapy (facit)-f fatigue score.

primary objective: -to determine the effectiveness of patient controlled methylphenidate as compared to placebo for the management of cancer related fatigue as determined by the functional assessment of chronic illness therapy (facit)-f fatigue score secondary objective * to assess the efficacy of as needed methylphenidate on pain, sedation and quality of life. * to assess the potential side effects of methylphenidate on appetite, insomnia and anxiety

Eligibility criteria:
inclusion criteria: * presence of fatigue on a numerical scale during the last 24 hours of more or equal to 4 on a 0 to 10 scale in which 0 equals no fatigue and 10 worst possible fatigue. * patients should describe fatigue as being present for a minimum of four days. * if patients are on opioids for the treatment of cancer pain, change of opioids is allowed. * no clinical evidence of cognitive failure, with normal mini mental state examination (mmse). a score of 24 is considered as normal. * sign written informed consent. * patients must be 18 years or older. * patient willing to keep a daily diary, engage in daily telephone follow up with a nurse, and after 7 days of treatment patient will return for a follow up visit. * patient must have telephone access to be contacted daily by the research nurse. * hemoglobin of \>/=10 g/dl within 2 weeks of enrollment. if the patient has not had blood drawn for a hemoglobin level in the past two weeks, one will be done to determine the eligibility. exclusion criteria: * major contraindication to methylphenidate i.e. hypersensitivity, anxiety, tension, agitation, or motor tics * currently on methylphenidate or has been on methylphenidate within the last 10 days. * inability to complete the baseline assessment forms or to understand the recommendations for participation in the study. * pregnant or lactating women. * patients taking mao inhibitors, tricyclic antidepressants and clonidine. * patients with glaucoma, history of marked anxiety disorder, or history of substance abuse. * cage questionnaire score for the last 2 years is 2 or above on a 0 to 4 scale * history of tourette's syndrome * patients with tachycardia and uncontrolled hypertension.